SPH4336 for advanced solid tumors with or without immunotherapy
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent, and your expected survival is at least 3 months.
- You have an advanced solid tumor (including a specific type of liposarcoma) that can’t be treated with curative surgery or other local treatments.
- For the dose-expansion part, you have at least one measurable tumor spot on scans (RECIST 1.1).
- Your blood tests and organ health (like liver/kidney/bone marrow) meet the study’s lab requirements.
- Any side effects from prior cancer treatments must have mostly improved (nerve side effects to mild level, other reversible side effects to very mild), as judged by the study doctor.
- You will use effective birth control from signing consent until after your last study dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
This phase 1 trial tests a new oral drug called SPH7485 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.